Evelo Biosciences Inc.

0.3630-0.0219-5.69%Vol 218.60K1Y Perf -80.76%
Dec 6th, 2023 16:00 DELAYED
BID0.3550 ASK0.3780
Open0.3734 Previous Close0.3849
Pre-Market- After-Market0.37
 - -  0.01 2.31%
Target Price
6.25 
Analyst Rating
— 0.00
Potential %
1.62K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
0.14 
Earnings Rating
Neutral
Market Cap6.87M 
Earnings Date
13th Nov 2023
Alpha-0.03 Standard Deviation0.44
Beta1.74 

Today's Price Range

0.35800.4000

52W Range

0.300744.20

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-6.67%
1 Month
13.21%
3 Months
-93.22%
6 Months
208.17%
1 Year
-80.76%
3 Years
-92.64%
5 Years
-96.44%
10 Years
-

TickerPriceChg.Chg.%
EVLO0.3630-0.0219-5.69
AAPL192.32-1.1000-0.57
GOOG131.43-0.9600-0.73
MSFT368.81-3.7150-1.00
XOM99.11-1.3300-1.32
WFC44.500.01000.02
JNJ156.62-1.9300-1.22
FB196.640.99000.51
GE119.81-0.4200-0.35
JPM156.31-1.6600-1.05
Financial StrengthValueIndustryS&P 500US Markets
2.60
2.70
0.82
5.88
-30.00
Leverage Ratio 9.10
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q03 2023-1.34-0.6650.75
Q02 2023-4.33-3.5518.01
Q04 2022-6.00-4.2030.00
Q03 2022-6.60-5.6015.15
Q02 2022-11.20-8.0028.57
Q01 2022-11.60-11.203.45
Q04 2021-12.20-10.8011.48
Q03 2021-0.57-0.63-10.53
Earnings Per EndEstimateRevision %Trend
12/2023 QR-1.66-16.08Negative
12/2023 FY-6.7058.13Positive
3/2024 QR-0.170.00-
12/2024 FY-3.2751.19Positive
Next Report Date-
Estimated EPS Next Report-1.34
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume218.60K
Shares Outstanding18.93K
Shares Float7.27M
Trades Count662
Dollar Volume80.88K
Avg. Volume749.51K
Avg. Weekly Volume270.28K
Avg. Monthly Volume1.28M
Avg. Quarterly Volume693.37K

Evelo Biosciences Inc. (NASDAQ: EVLO) stock closed at 0.3849 per share at the end of the most recent trading day (a -3.77% change compared to the prior day closing price) with a volume of 158.67K shares and market capitalization of 6.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 98 people. Evelo Biosciences Inc. CEO is Balkrishan Gill.

The one-year performance of Evelo Biosciences Inc. stock is -80.76%, while year-to-date (YTD) performance is -76.09%. EVLO stock has a five-year performance of -96.44%. Its 52-week range is between 0.3007 and 44.2, which gives EVLO stock a 52-week price range ratio of 0.14%

Evelo Biosciences Inc. currently has a PE ratio of -0.80, a price-to-book (PB) ratio of 16.44, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -117.99%, a ROC of -152.34% and a ROE of -564.20%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Evelo Biosciences Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.34 for the next earnings report. Evelo Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Evelo Biosciences Inc. is (0), with a target price of $6.25, which is +1 621.76% compared to the current price. The earnings rating for Evelo Biosciences Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Evelo Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Evelo Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 24.21, ATR14 : 0.14, CCI20 : -41.14, Chaikin Money Flow : 0.08, MACD : -0.29, Money Flow Index : 68.77, ROC : -47.62, RSI : 31.39, STOCH (14,3) : 8.38, STOCH RSI : 0.00, UO : 46.76, Williams %R : -91.62), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Evelo Biosciences Inc. in the last 12-months were: Bodmer Mark (Sold 0 shares of value $0 ), Bodmer Mark (Sold 100 602 shares of value $15 307 ), Duncan Mchale (Sold 0 shares of value $0 ), Duncan Mchale (Sold 76 687 shares of value $11 961 ), Simba Gill (Sold 0 shares of value $0 ), Simba Gill (Sold 2 510 shares of value $11 173 ), Stephen J. Carriere (Sold 0 shares of value $0 ), Stephen J. Carriere (Sold 151 shares of value $160 ), Thorell Marella (Sold 0 shares of value $0 ), Thorell Marella (Sold 7 814 shares of value $20 975 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0 (0.00 %)
1 (33.33 %)
Moderate Buy
0
0 (0.00 %)
0 (0.00 %)
Hold
0
2 (100.00 %)
2 (66.67 %)
Moderate Sell
0
0 (0.00 %)
0 (0.00 %)
Strong Sell
0
0 (0.00 %)
0 (0.00 %)
Summary Rating-
0.00
Hold
3.00
Moderate Buy
2.33

Evelo Biosciences Inc.

Evelo Biosciences Inc operates as a bio-technology company. It is an immuno-microbiome company, develops immunotherapies for the treatment of cancer, oncology, neuroinflammation, metabolism, autoimmune, and inflammatory diseases. The company develops therapies for the treatment of the gut-body network.

CEO: Balkrishan Gill

Telephone: +1 617 577-0300

Address: 620 Memorial Drive, Cambridge 02139, MA, US

Number of employees: 98

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

 

News

Stocktwits